The Human Genome Diversity Project: An Ethnography of Scientific Practice (Cambridge Studies in Society and the Life Sciences)
Medical News Today (Free subscription) | 9 hours ago
Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
Business Wire (Free subscription) | yesterday
ROCKVILLE, Md. & MONTREAL--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. “We are pleased to initiate this first human study of HGS1029 in lymphoid...
Fiercebiotech (Free subscription) | 19/11/2009
ImmuPharma's shares dropped 19 percent following the announcement that a Phase II study of the potential lupus treatment Lupuzor did not reach statistical significance. But CEO Dimitri Dimitriou claims that the market has misinterpreted the study results, and that the subset of patients ImmuPharma intended to test did respond to the drug. Lupuzor met its primary endpoint, but not statistical significance...
Business Wire (Free subscription) | 16/11/2009
ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional...
Market Wire (Free subscription) | 11/11/2009
LONDON (MARKET WIRE) Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities. Today we began research on PAETEC Holding Corp. (NASDAQ: PAET), Akamai Technologies Inc. (NASDAQ: AKAM), Cerner Corp. (NASDAQ: CERN), Infosys Technologies Limited (NASDAQ: INFY), Human...
SeekingAlpha.com (Free subscription) | 05/11/2009
Zacks.com submits: Human Genome Sciences, Inc. ( HGSI ) reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for the quarter was primarily attributable to increased revenues from manufacturing and development services and lower operating...
Jim Cramer's Mad Money (Free subscription) | 05/11/2009
Jim Cramer’s Mad Money Stock Picks for Wednesday November 4 2009. These are all of Jim Cramer’s stock picks that are a Buy! I bold my picks. Buy: Tessera Technologies (TSRA) EnCana (ECA) Wendy’s/Arby’s Group (WEN) Wellpoint (WLP) Immunogen (IMGN) Human Genome Sciences (HGSI) Goldman Sachs (GS) Sims Group (SMS) Sell: Seattle Genetics (SGEN) Always do your own research as these...
Madd Money (Free subscription) | 05/11/2009
Bullish Human Genome Sciences (HGSI), Goldman Sachs Group Inc. (GS), Sims Metal Management Limited (SMS), EnCana Corporation (ECA) and Wendy’s/Arby’s Group Inc. (WEN). Bearish Seattle Genetics Inc. (NASDAQ:SGEN). Join the fastest growing community of small cap investors at Stockhideout.com
Volume Spike Investor (Free subscription) | 03/11/2009
Human Genome Sciences Inc. (NASDAQ: HGSI) was lower this morning and had been off our radar as a result after yesterday’s huge moves. Yet at 1:30 PM EST we have just hit the virtual double on average daily volume. Shares are up 8% at $27.34 on about 16.2 million shares versus and average volume of [...]
Medical News Today (Free subscription) | 03/11/2009
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology.
Scientific American (Free subscription) | 03/11/2009
Systemic lupus is the most common form of the autoimmune disease, lupus , which afflicts about 5 million people worldwide and causes a slew of symptoms including fever, pain and swelling. Now, sufferers of systemic lupus may be closer to a new drug to treat their symptoms, according to the results of a study announced yesterday. If approved to market, the drug, which was developed by Human Genome...
The Washington Times (Free subscription) | 03/11/2009
NEW YORK (AP) | Human Genome Sciences and GlaxoSmithKline said Monday that their experimental lupus treatment passed another key goal on its path to potentially becoming the first new drug for the disease in decades. Shares of Human Genome Sciences soared 35 percent with the report. Wall Street and researchers anticipated study data from the trial, hoping it would confirm positive results from a prior...
Medical News Today (Free subscription) | 03/11/2009
The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.
Medical News Today (Free subscription) | 03/11/2009
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA™ (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology.
Washington Post (Free subscription) | 03/11/2009
Rockville-based Human Genome Sciences announced Monday that its experimental lupus drug has completed its final round of testing at a higher dose and will be headed to the Food and Drug Administration for approval.
Videos